A Phase III, Randomized, Multicenter, Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients with Extensive Disease (St

Protocol: 
AAAR2668
Phase: 
III

A Phase III, Randomized, Multicenter, Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients with Extensive Disease (St

Are you Eligible? (Inclusion Criteria)

Patients must:
1) Be ≥18 years at the time of Screening
2) Have not received prior treatment for SCLC
3) Have histologically or cytologically documented extensive disease
4) No history of autoimmune disease (such as colitis, Crohn's disease,
lupus)
5) Be fully active or restricted in physically strenuous activity but able
to carry out
work of a light or sedentary nature, e.g., light house work, office work

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States